A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial

In this placebo-controlled phase II randomized clinical trial, 103 human immunodeficiency virus type 1 (HIV-1)-infected patients under cART (combined antiretroviral treatment) were randomized 2:1 to receive either 3 doses of DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, and gp160) at week 0 (W0...

Descripción completa

Detalles Bibliográficos
Autores principales: Lévy, Y., Lacabaratz, C., Lhomme, E., Wiedemann, A., Bauduin, C., Fenwick, C., Foucat, E., Surenaud, M., Guillaumat, L., Boilet, V., Rieux, V., Bouchaud, O., Girard, P.-M., Molina, J.-M., Morlat, P., Hocqueloux, L., Richert, L., Pantaleo, G., Lelièvre, J. D., Thiébaut,, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104102/
https://www.ncbi.nlm.nih.gov/pubmed/33568510
http://dx.doi.org/10.1128/JVI.02165-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104102/
https://www.ncbi.nlm.nih.gov/pubmed/33568510
http://dx.doi.org/10.1128/JVI.02165-20

Ejemplares similares